Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.52
DXCM's Cash-to-Debt is ranked lower than
52% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. DXCM: 1.52 )
Ranked among companies with meaningful Cash-to-Debt only.
DXCM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 19.27 Max: No Debt
Current: 1.52
Equity-to-Asset 0.45
DXCM's Equity-to-Asset is ranked lower than
51% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DXCM: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
DXCM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.63  Med: 0.72 Max: 0.92
Current: 0.45
-0.63
0.92
Debt-to-Equity 0.93
DXCM's Debt-to-Equity is ranked higher than
52% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. DXCM: 0.93 )
Ranked among companies with meaningful Debt-to-Equity only.
DXCM' s Debt-to-Equity Range Over the Past 10 Years
Min: -22.5  Med: 0.04 Max: 22.72
Current: 0.93
-22.5
22.72
Piotroski F-Score: 5
Altman Z-Score: 8.38
Beneish M-Score: -3.48
WACC vs ROIC
3.66%
-40.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -12.42
DXCM's Operating Margin % is ranked lower than
59% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. DXCM: -12.42 )
Ranked among companies with meaningful Operating Margin % only.
DXCM' s Operating Margin % Range Over the Past 10 Years
Min: -1008.77  Med: -57.24 Max: -8.29
Current: -12.42
-1008.77
-8.29
Net Margin % -10.27
DXCM's Net Margin % is ranked lower than
58% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. DXCM: -10.27 )
Ranked among companies with meaningful Net Margin % only.
DXCM' s Net Margin % Range Over the Past 10 Years
Min: -991.53  Med: -56.57 Max: -8.64
Current: -10.27
-991.53
-8.64
ROE % -22.83
DXCM's ROE % is ranked lower than
66% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. DXCM: -22.83 )
Ranked among companies with meaningful ROE % only.
DXCM' s ROE % Range Over the Past 10 Years
Min: -259.33  Med: -45.51 Max: -19.97
Current: -22.83
-259.33
-19.97
ROA % -13.77
DXCM's ROA % is ranked lower than
63% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. DXCM: -13.77 )
Ranked among companies with meaningful ROA % only.
DXCM' s ROA % Range Over the Past 10 Years
Min: -117.86  Med: -46.68 Max: -13.77
Current: -13.77
-117.86
-13.77
ROC (Joel Greenblatt) % -48.75
DXCM's ROC (Joel Greenblatt) % is ranked lower than
59% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. DXCM: -48.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DXCM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -828.4  Med: -228.52 Max: -47.64
Current: -48.75
-828.4
-47.64
3-Year Revenue Growth Rate 45.00
DXCM's 3-Year Revenue Growth Rate is ranked higher than
93% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. DXCM: 45.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DXCM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 38.1 Max: 103.1
Current: 45
0
103.1
3-Year EBITDA Growth Rate 24.10
DXCM's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. DXCM: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DXCM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.8 Max: 24.1
Current: 24.1
0
24.1
3-Year EPS without NRI Growth Rate 22.90
DXCM's 3-Year EPS without NRI Growth Rate is ranked higher than
75% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. DXCM: 22.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DXCM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -40  Med: -15.7 Max: 47.3
Current: 22.9
-40
47.3
GuruFocus has detected 1 Warning Sign with DexCom Inc $DXCM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DXCM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DXCM Guru Trades in Q3 2016

George Soros 2,576 sh (New)
Jim Simons Sold Out
Mario Gabelli 41,600 sh (-0.72%)
Ron Baron 851,477 sh (-5.57%)
Steven Cohen 183,600 sh (-29.66%)
John Paulson 43,500 sh (-64.78%)
» More
Q4 2016

DXCM Guru Trades in Q4 2016

Jim Simons 137,643 sh (New)
John Paulson 293,200 sh (+574.02%)
George Soros 5,300 sh (+105.75%)
Steven Cohen 192,600 sh (+4.90%)
Steven Cohen 200,000 sh (unchged)
Ron Baron 839,027 sh (-1.46%)
Mario Gabelli 37,300 sh (-10.34%)
» More
Q1 2017

DXCM Guru Trades in Q1 2017

Jim Simons 295,143 sh (+114.43%)
Ron Baron 789,027 sh (-5.96%)
Mario Gabelli 34,000 sh (-8.85%)
John Paulson 240,700 sh (-17.91%)
George Soros 2,800 sh (-47.17%)
Steven Cohen 44,657 sh (-76.81%)
» More
Q2 2017

DXCM Guru Trades in Q2 2017

Steven Cohen 374,566 sh (+738.76%)
George Soros Sold Out
Jim Simons Sold Out
Mario Gabelli 33,000 sh (-2.94%)
Ron Baron 680,810 sh (-13.72%)
John Paulson 183,400 sh (-23.81%)
» More
» Details

Insider Trades

Latest Guru Trades with DXCM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2017-06-30 Reduce -13.72%0.05%$66.84 - $84.73 $ 69.15-7%680,810
John Paulson 2017-06-30 Reduce -23.81%0.06%$66.84 - $84.73 $ 69.15-7%183,400
Mario Gabelli 2017-06-30 Reduce -2.94%$66.84 - $84.73 $ 69.15-7%33,000
George Soros 2017-06-30 Sold Out 0.01%$66.84 - $84.73 $ 69.15-7%0
Ron Baron 2017-03-31 Reduce -5.96%0.02%$58.25 - $85.49 $ 69.15-11%789,027
John Paulson 2017-03-31 Reduce -17.91%0.04%$58.25 - $85.49 $ 69.15-11%240,700
Mario Gabelli 2017-03-31 Reduce -8.85%$58.25 - $85.49 $ 69.15-11%34,000
George Soros 2017-03-31 Reduce -47.17%$58.25 - $85.49 $ 69.15-11%2,800
Ron Baron 2016-12-31 Reduce -1.46%0.01%$59.7 - $84.98 $ 69.15-2%839,027
John Paulson 2016-12-31 Add 574.02%0.19%$59.7 - $84.98 $ 69.15-2%293,200
Mario Gabelli 2016-12-31 Reduce -10.34%$59.7 - $84.98 $ 69.15-2%37,300
George Soros 2016-12-31 Add 105.75%0.01%$59.7 - $84.98 $ 69.15-2%5,300
Ron Baron 2016-09-30 Reduce -5.57%0.02%$77.55 - $95.8 $ 69.15-22%851,477
John Paulson 2016-09-30 Reduce -64.78%0.06%$77.55 - $95.8 $ 69.15-22%43,500
Mario Gabelli 2016-09-30 Reduce -0.72%$77.55 - $95.8 $ 69.15-22%41,600
George Soros 2016-09-30 New Buy0.01%$77.55 - $95.8 $ 69.15-22%2,576
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 3841
Compare:NAS:EXAS, NAS:INCR, NYSE:BIO, NYSE:CRL, NAS:PRAH, NAS:BRKR, NYSE:PKI, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:NEOG, NAS:MYGN, NAS:QDEL, NAS:FMI, NAS:AXDX, NAS:VREX, NAS:MEDP, NAS:GHDX, NAS:BEAT, NAS:ABAX » details
Traded in other countries:DC4.Germany, DXCM.Mexico,
Headquarter Location:USA
DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company's product line includes SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing systems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. To address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body's glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.

Guru Investment Theses on DexCom Inc

Baron Funds Comments on DexCom Inc. - Jan 14, 2016

Another health care holding, DexCom, Inc., (NASDAQ:DXCM) sells a continuous glucose monitoring system for diabetics. Although this is an unusual investment for the portfolio because of its extended trading multiple, we think DexCom’s fundamentals justify our investment. Over the last three years, DexCom has launched a series of new products driving a dramatic acceleration in revenue growth. We believe the company’s new product pipeline remains robust and will lead to further adoption among the growing population of diabetics.



From the Baron Funds Small Cap Fund winter newsletter 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about DexCom Inc

7 of the Worst-Performing Stocks in Gurus' Portfolios Stocks with negative 6-month performances
While gurus hold positions in these companies, the stock price and returns continue to fall. These are the worst-performing stocks over the last three months with a long-term presence in more than four gurus’ portfolios. Read more...

Ratios

vs
industry
vs
history
PB Ratio 17.03
DXCM's PB Ratio is ranked lower than
97% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. DXCM: 17.03 )
Ranked among companies with meaningful PB Ratio only.
DXCM' s PB Ratio Range Over the Past 10 Years
Min: 3.88  Med: 19.02 Max: 194.65
Current: 17.03
3.88
194.65
PS Ratio 9.40
DXCM's PS Ratio is ranked lower than
76% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. DXCM: 9.40 )
Ranked among companies with meaningful PS Ratio only.
DXCM' s PS Ratio Range Over the Past 10 Years
Min: 6.16  Med: 14.28 Max: 239.59
Current: 9.4
6.16
239.59
Price-to-Operating-Cash-Flow 116.45
DXCM's Price-to-Operating-Cash-Flow is ranked lower than
100% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. DXCM: 116.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DXCM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 89.37  Med: 148.99 Max: 1409.38
Current: 116.45
89.37
1409.38
EV-to-EBIT -76.89
DXCM's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DXCM: -76.89 )
Ranked among companies with meaningful EV-to-EBIT only.
DXCM' s EV-to-EBIT Range Over the Past 10 Years
Min: -391.9  Med: -16.65 Max: -1.6
Current: -76.89
-391.9
-1.6
EV-to-EBITDA -96.20
DXCM's EV-to-EBITDA is ranked lower than
99.99% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. DXCM: -96.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
DXCM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -764.5  Med: -18.1 Max: -1.7
Current: -96.2
-764.5
-1.7
EV-to-Revenue 9.27
DXCM's EV-to-Revenue is ranked lower than
73% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. DXCM: 9.27 )
Ranked among companies with meaningful EV-to-Revenue only.
DXCM' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.3  Med: 14.7 Max: 200.4
Current: 9.27
5.3
200.4
Current Ratio 6.25
DXCM's Current Ratio is ranked lower than
62% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. DXCM: 6.25 )
Ranked among companies with meaningful Current Ratio only.
DXCM' s Current Ratio Range Over the Past 10 Years
Min: 1.92  Med: 3.98 Max: 23.47
Current: 6.25
1.92
23.47
Quick Ratio 5.84
DXCM's Quick Ratio is ranked lower than
60% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. DXCM: 5.84 )
Ranked among companies with meaningful Quick Ratio only.
DXCM' s Quick Ratio Range Over the Past 10 Years
Min: 1.65  Med: 3.6 Max: 23.47
Current: 5.84
1.65
23.47
Days Inventory 79.82
DXCM's Days Inventory is ranked lower than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. DXCM: 79.82 )
Ranked among companies with meaningful Days Inventory only.
DXCM' s Days Inventory Range Over the Past 10 Years
Min: 35.66  Med: 54.23 Max: 79.82
Current: 79.82
35.66
79.82
Days Sales Outstanding 58.67
DXCM's Days Sales Outstanding is ranked higher than
64% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. DXCM: 58.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXCM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.96  Med: 59.63 Max: 71.25
Current: 58.67
16.96
71.25
Days Payable 30.16
DXCM's Days Payable is ranked lower than
75% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. DXCM: 30.16 )
Ranked among companies with meaningful Days Payable only.
DXCM' s Days Payable Range Over the Past 10 Years
Min: 21.26  Med: 31.59 Max: 56.11
Current: 30.16
21.26
56.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
DXCM's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. DXCM: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DXCM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137.6  Med: -14.7 Max: -4.6
Current: -5.3
-137.6
-4.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 109.76
DXCM's Price-to-Net-Cash is ranked lower than
99.99% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.16 vs. DXCM: 109.76 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DXCM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.94  Med: 45.45 Max: 995
Current: 109.76
4.94
995
Price-to-Net-Current-Asset-Value 27.88
DXCM's Price-to-Net-Current-Asset-Value is ranked lower than
91% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. DXCM: 27.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DXCM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.88  Med: 25.72 Max: 53.03
Current: 27.88
4.88
53.03
Price-to-Tangible-Book 17.51
DXCM's Price-to-Tangible-Book is ranked lower than
93% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. DXCM: 17.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DXCM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.69  Med: 17.81 Max: 143.95
Current: 17.51
4.69
143.95
Price-to-Intrinsic-Value-Projected-FCF 52.79
DXCM's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
100% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. DXCM: 52.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DXCM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 52.6  Med: 129.27 Max: 282.77
Current: 52.79
52.6
282.77
Price-to-Median-PS-Value 0.65
DXCM's Price-to-Median-PS-Value is ranked higher than
74% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. DXCM: 0.65 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DXCM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.01 Max: 2027
Current: 0.65
0.56
2027
Earnings Yield (Greenblatt) % -1.30
DXCM's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. DXCM: -1.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DXCM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -62.1  Med: -6 Max: -0.3
Current: -1.3
-62.1
-0.3

More Statistics

Revenue (TTM) (Mil) $632.70
EPS (TTM) $ -0.76
Beta0.23
Short Percentage of Float16.21%
52-Week Range $57.68 - 94.79
Shares Outstanding (Mil)86.56

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 723 956 1,260 1,576
EPS ($) -0.83 -0.09 0.85 1.44
EPS without NRI ($) -0.83 -0.09 0.85 1.44
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}